| Adenovirus and immunotherapy: advancing cancer treatment by combination M Sato-Dahlman, CJ LaRocca, C Yanagiba, M Yamamoto Cancers 12 (5), 1295, 2020 | 42 | 2020 |
| Preliminary data from a phase 1 study of JSP191, an anti-CD117 monoclonal antibody, in combination with low dose irradiation and fludarabine conditioning is well-tolerated … LS Muffly, CJ Lee, AP Gandhi, A Varma, B Scott, HS Kwon, C Yanagiba, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | 4 | 2022 |
| Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells H Yoshida, M Sato-Dahlman, P Hajeri, K Jacobsen, L Koodie, ... Translational oncology 14 (2), 100997, 2021 | 3 | 2021 |
| Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable … A Gandhi, A Artz, CJ Lee, A Varma, BL Scott, HS Kwon, M Youn, ... Blood 142, 470, 2023 | | 2023 |
| GVHD ASSESSMENT IN PHASE 1 STUDY OF BRIQUILIMAB (JSP191), LOW DOSE IRRADIATION AND FLUDARABINE CONDITIONING IN OLDER ADULTS WITH MDS/AML UNDERGOING ALLOGENEIC HCT M Youn, L Muffly, A Artz, C Lee, A Gandhi, A Varma, B Scott, C Yanagiba, ... BONE MARROW TRANSPLANTATION 58 (SUPP 1), 306-307, 2023 | | 2023 |
| Subanalysis from Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in … LS Muffly, CJ Lee, AP Gandhi, A Varma, B Scott, HS Kwon, M Youn, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | | 2023 |
| Immune Biomarkers Associated with Chronic Gvhd in Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine … M Youn, LS Muffly, AS Artz, CJ Lee, AP Gandhi, A Varma, B Scott, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | | 2023 |
| Sa285 EFFICIENT SYSTEMIC TREATMENT WITH MESOTHELIN-TARGETED ONCOLYTIC ADENOVIRUS IN PANCREATIC CANCER M Sato-Dahlman, K Jacobsen, C Yanagiba, M Yamamoto Gastroenterology 160 (6), S-469, 2021 | | 2021 |
| Investigation of Human Adenoviral Replication Efficacies in Murine Cell Lines for the Generation of an Immunocompetent Mouse Model C Yanagiba, MS Dahlman, H Yoshida, K Jacobsen, M Yamamoto MOLECULAR THERAPY 29 (4), 320-320, 2021 | | 2021 |
| Efficacy of Systemic Administration of Mesothelin-Targeted Oncolytic Adenovirus In Pancreatic Cancer M Sato-Dahlman, P Hajeri, K Jacobsen, C Yanagiba, M Yamamoto MOLECULAR THERAPY 29 (4), 322-323, 2021 | | 2021 |
| Development of Systemically Applicable Cancer-Targeted Oncolytic Adenovirus in Pancreatic Cancer M Sato-Dahlman, Y Miura, P Hajeri, K Jacobsen, C Yanagiba, ... MOLECULAR THERAPY 28 (4), 164-164, 2020 | | 2020 |
| Intravenous Application of Mesothelin-Targeted Oncolytic Adenovirus to Pancreatic Cancer M Sato-Dahlman, Y Miura, P Hajeri, H Yoshida, K Jacobsen, C Yanagiba, ... MOLECULAR THERAPY 27 (4), 124-124, 2019 | | 2019 |
| Systemic treatment with mesothelin-targeted oncolytic adenovirus shows efficacy patient-derived xenograft of pancreatic cancer M Sato-Dahlman, Y Miura, P Hajeri, H Yoshida, K Jacobsen, C Yanagiba, ... Cancer Research 78 (13_Supplement), 5921-5921, 2018 | | 2018 |
| Efficient Systemic Treatment with Mesothelin-Targeted Oncolytic Adenovirus in Patient-Derived Xenograft (PDX) Model of Pancreatic Cancer M Sato-Dahlman, Y Miura, P Hajeri, H Yoshida, K Jacobsen, C Yanagiba, ... MOLECULAR THERAPY 26 (5), 330-330, 2018 | | 2018 |
